UBS MSCI Switzerland 20/35 UCITS ETF hEUR acc

What this fund is

UBS MSCI Switzerland 20/35 UCITS ETF hEUR acc is an exchange-traded fund (ETF) from UBS, traded under the ticker 0A5L (ISIN LU1169830103). In a single purchase you get a diversified basket of holdings rather than a stake in just one business. In plain terms it is about owning small slices of companies, so you share in their growth when they do well — and their falls when they don't, focused on the European market. Rather than a manager picking stocks, it simply replicates the MSCI Switzerland 20/35 index — the passive, low-cost approach, and its largest holdings include ROCHE HLDG PC PRP, NOVARTIS AG-REG and NESTLE SA-REG. By geography it is weighted towards ~75.7% Switzerland.

By industry it concentrates most in ~30.9% Health Care and ~15.6% Financials. Investors often use a broad fund like this as a long-term 'core' holding — a single building block that covers much of a global portfolio in one trade. Its ongoing charge (TER) is 0.23% a year — about €23 a year on a €10,000 holding, taken automatically from the fund. It is an accumulating share class: dividends are rolled straight back in, compounding your returns rather than landing in your account as cash. It holds the underlying investments directly (physical replication); it is domiciled in Luxembourg and UCITS-regulated, a European standard built to protect everyday investors and trades in EUR.

Its price has swung about 11.7% over the past year — a gauge of how much the value moves, not a judgement of quality. It launched in 2020. Like any investment, it can lose value as well as gain, and what it did before does not predict what it will do next. (Fund data sourced from UBS.)